CureApp Valuation, Funding & Investors

CureApp is valued at $261M as of August 2022.

Last CureApp valuation

$261M

Series G · Aug 2022

Last CureApp funding round

$52M

Series G · Aug 2022

Cumulative funding CureApp raised

$109M

across 6 funding rounds

Key investors in CureApp

CureApp Overview

About CureApp

CureApp is a Tokyo-headquartered digital therapeutics company pioneering medical apps with proven clinical efficacy. It launched Japan's first nicotine addiction treatment app in February 2015 through collaboration with Keio University School of Medicine's Division of Pulmonary Medicine. The firm conducts multicenter clinical trials for apps targeting hypertension, alcohol dependence, and psychiatric disorders. CureApp holds regulatory approvals as medical devices from Japan's Ministry of Health, Labour and Welfare, positioning it as a leader in software-based behavioral therapies delivered via smartphones.


Founded

2014

HQ

JapanTokyo

Status

Privately held

Customer focus

B2C

Revenue model

Subscription

Valuation

$261M (Aug 2022)

CureApp Valuation

CureApp is currently valued at $261M, based on its Series G in August 2022.

The $52M round was led by Carlyle Group.

CureApp valuation by funding round

CureApp valuation by funding round
DateStageValuation
Aug 2022Series G$261M

CureApp Funding History

CureApp has raised a total of $109M across 6 funding rounds.

CureApp's first fundraising round was a $800K seed round in October 2015. The most recent completed round was a $52M Series G in August 2022.

CureApp funding rounds

CureApp funding rounds
DateStageInvestorsRaisedValuationDeal Summary
Aug 2022Series GCarlyle Group (lead)$52M$261MCureApp is a Tokyo-based digital therapeutics startup founded in 2014 by medical doctors Kota Satake (CEO) and Susumu Suzuki (CTO), specializing in prescription digital therapeutics apps developed in collaboration with institutions like Keio University School of Medicine and Jichi Medical University. The company released a smoking cessation app in 2015, which received regulatory approval as digital therapeutics in August 2020 and insurance coverage in December 2020; its hypertension app gained approval in April 2022, demonstrating a 10.7% reduction in cardiovascular risk in trials. CureApp is also advancing pipelines for non-alcoholic steatohepatitis (NASH), alcoholism, cancer, and chronic heart failure. On August 16, 2022, CureApp secured approximately 7 billion yen ($51.5 million) in its Series G funding round from Carlyle, bringing total funding to 13.4 billion yen ($98.6 million). Carlyle is taking a minority stake and appointing a director to the board to aid global expansion, sales networks, marketing, and product development leveraging its healthcare expertise. Funds will support rollout of the hypertension app and pipeline advancement. The investment positions CureApp amid a growing global DTx market projected to reach $13.8 billion by 2027 at 20.5% CAGR.
Mar 2021Series DITOCHU Technology Ventures; Shoko Chukin Bank; Koshidaka Holdings; SIIF; Shinsei Bank; Toyoshima; Daiichi Life Group; Sumitomo Mitsui Trust Investment; Healthcare Innovation; Saisei Ventures; SMBC Venture Capital$19M--
Jul 2019Series CKoshidaka Holdings; INTAGE HOLDINGS; Daiichi Life Group; Mori Trust$20M-CureApp is a Japanese digital therapeutics company founded in 2014, developing prescription digital apps for conditions like nicotine addiction, hypertension, alcohol addiction, NASH, oncology, and chronic heart failure. Their first product, CureApp® Smoking Cessation, received medical device approval in 2020 and national health insurance reimbursement in Japan. The hypertension app achieved world-first approval as a standalone software medical device in April 2022. They also offer corporate wellness programs like ascure Smoking Cessation implemented at over 230 companies. On July 5, 2019, CureApp raised funds in a Series C round led by investors including Dai-ichi Life Insurance, with total funding across 10 rounds reaching $90.61M as of 2024. The exact amount for this round is reported as $20.3M in some lists. Prior to this, the company had completed large-scale phase III clinical studies for digital therapeutics in Japan, pioneering the field. CureApp continued growth with later rounds like Series G in 2022 and incubator programs through 2024, plus partnerships such as with Jichi Medical University for hypertension trials starting December 2019 and Daiichi Sankyo for oncology apps. The company operates in the digital health space, focusing on evidence-based personalized treatments to reduce medical costs and address unmet needs in chronic diseases.
Feb 2018Series BITOCHU Technology Ventures; Cyberdyne; ITOCHU; Mizuho Capital; SBI Investment; Daiichi Life Group; Beyond Next Ventures; Mitsubishi UFJ Capital; Saison Ventures; Keio Innovation Initiative; Iwagin Jigyo Souzou Capital; Chibagin Capital$14M--
Feb 2017Series ABeyond Next Ventures (lead); SBI Investment; Keio Innovation Initiative$3M-CureApp was founded in 2014 by Dr. Kohta Satake and created Japan's first therapeutic app category. The company is ranked among the NEXT Unicorns in the Nikkei newspaper's proprietary valuation survey. Beyond Next Ventures made CureApp its inaugural portfolio investment from their inaugural fund in 2015, and the company has continued to develop evidence-based medical devices with clinical validation.
Oct 2015SeedBeyond Next Ventures (lead)$800K--

Who has invested in CureApp?

24 investors have backed CureApp across its funding rounds, including Beyond Next Ventures, Daiichi Life Group, SBI Investment, ITOCHU Technology Ventures, Keio Innovation Initiative and Koshidaka Holdings.

Lead investors include Carlyle Group and Beyond Next Ventures.


CureApp Investors

Investors in CureApp by funding rounds participated
InvestorHQRoundsRoleFirst check
Daiichi Life GroupJapanTokyo3ParticipantFeb 2018
Beyond Next VenturesJapanTokyo3LeadOct 2015
ITOCHU Technology VenturesJapanTokyo2ParticipantFeb 2018
Koshidaka HoldingsJapanTokyo2ParticipantJul 2019
SBI InvestmentJapanTokyo2ParticipantFeb 2017
Keio Innovation InitiativeJapanTokyo2ParticipantFeb 2017
Shoko Chukin BankJapanJapan1ParticipantMar 2021
INTAGE HOLDINGSJapanTokyo1ParticipantJul 2019
SIIFJapanTokyo1ParticipantMar 2021
Shinsei BankJapanTokyo1ParticipantMar 2021
ToyoshimaJapanNagoya1ParticipantMar 2021
CyberdyneJapanJapan1ParticipantFeb 2018
ITOCHUJapanTokyo1ParticipantFeb 2018

This data is available for Pro users. Sign up to see all 24 CureApp investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

CureApp Competitors

CureApp competitors include listed companies like Nyxoah and Oneview Healthcare, and private ones like Biopeak, Benovymed Healthcare Group, Qure AI and Slingshot AI.

Public and private companies comparable to CureApp
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
BiopeakIndiaBangalorePrivate$2M-$250M125.0x
Benovymed Healthcare GroupIndiaDelhiPrivate--$241M-
Qure AIIndiaMumbaiPrivate$19M-$240M12.6x
Slingshot AIUnited StatesSan Francisco, CAPrivate$10M-$220M22.0x
NyxoahBelgiumBelgiumPublicly listed$12M($97M)$162M3.2x
Oneview HealthcareUnited StatesUnited StatesPublicly listed$14M($12M)$100M7.1x

CureApp Public Comps

CureApp is still privately-owned, but its public comps include Nyxoah, Oneview Healthcare, Kooth, Saluda Medical, DarioHealth, Welby, Physitrack, iXensor, Sphere and Helus Pharma.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Nyxoah$12M($97M)9.5x3.2x(1.1x)(1.4x)
Oneview Healthcare$14M($12M)7.1x7.1x(8.2x)(11.3x)
Kooth$85M$13M0.7x0.7x4.6x4.3x
Saluda Medical$70M($144M)----
DarioHealth$22M($36M)3.9x4.0x(2.4x)(4.2x)
Welby$4M($3M)4.5x4.5x(5.7x)-
Physitrack$16M($2M)1.2x1.2x(8.5x)6.2x
iXensor$844K($1M)8.9x-(6.0x)-

This data is available for Pro users. Sign up to see all CureApp competitors and their valuation data.

Start Free Trial

Common questions about CureApp

When was CureApp founded?CureApp was founded in 2014.
Where is CureApp headquartered?CureApp is headquartered in Tokyo, Japan.
Is CureApp publicly listed?No, CureApp is a private, VC-backed company.
What is CureApp's valuation?CureApp was last valued at $261M in its Series G in August 2022.
How much funding has CureApp raised?CureApp has raised $109M across 6 funding rounds.
What was CureApp's last funding round?CureApp's last funding round was a $52M Series G in August 2022, led by Carlyle Group.
Who are CureApp's investors?CureApp's investors include Daiichi Life Group, Beyond Next Ventures, ITOCHU Technology Ventures, Koshidaka Holdings, SBI Investment, Keio Innovation Initiative, Shoko Chukin Bank, INTAGE HOLDINGS, SIIF, Shinsei Bank and 14 others.
Which companies are comparable to CureApp?Companies comparable to CureApp include Biopeak, Benovymed Healthcare Group, Qure AI, Slingshot AI, Nyxoah and Oneview Healthcare.

See companies similar to CureApp

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial